KPIs & Operating Metrics(New)
Growth Metrics

Bristol Myers Squibb (BMY) EPS (Basic) (2016 - 2026)

Bristol Myers Squibb has reported EPS (Basic) over the past 18 years, most recently at $1.31 for Q1 2026.

  • Quarterly EPS (Basic) rose 8.26% to $1.31 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.57 through Mar 2026, up 33.21% year-over-year, with the annual reading at $3.47 for FY2025, 178.68% up from the prior year.
  • EPS (Basic) was $1.31 for Q1 2026 at Bristol Myers Squibb, up from $0.54 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $1.31 in Q1 2026 and troughed at -$5.89 in Q1 2024.
  • The 5-year median for EPS (Basic) is $0.83 (2024), against an average of $0.42.
  • Year-over-year, EPS (Basic) tumbled 645.37% in 2024 and then skyrocketed 1250.0% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at $0.96 in 2022, then fell by 9.38% to $0.87 in 2023, then tumbled by 95.4% to $0.04 in 2024, then skyrocketed by 1250.0% to $0.54 in 2025, then skyrocketed by 142.59% to $1.31 in 2026.
  • Per Business Quant, the three most recent readings for BMY's EPS (Basic) are $1.31 (Q1 2026), $0.54 (Q4 2025), and $1.08 (Q3 2025).